Nkarta, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
NKTX Nasdaq 2834 www.nkartatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nkarta, Inc.

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 - Nov 6th, 2026 2:01 pm
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update - Nov 5th, 2026 2:34 pm
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance - Sep 27th, 2026 1:02 pm
Nkarta to Participate in September Investor Conferences - Sep 10th, 2026 5:00 am
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 - Sep 8th, 2026 5:00 am
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - Aug 10th, 2026 2:24 pm
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development - Jul 22nd, 2026 11:30 pm
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Jun 26th, 2026 6:45 am
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - May 14th, 2026 5:12 am
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - May 12th, 2026 2:01 pm
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - Apr 17th, 2026 8:28 am
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers - Apr 15th, 2026 2:01 pm
Nkarta to Participate in Needham Virtual Healthcare Conference - Apr 9th, 2026 5:00 am
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights - Mar 25th, 2026 2:01 pm
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight - Mar 10th, 2026 3:31 pm
Nkarta to Participate in March Investor Conferences - Feb 27th, 2026 6:00 am
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses - Jan 21st, 2026 3:58 pm
We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully - Dec 4th, 2025 5:24 am